Aisling E. Courtney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aisling E. Courtney has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Peter Maxwell
Centre for Public Health, Queen’s University Belfast, Belfast, UK
3 shared publications - Clare McKeaveney
School of Nursing and Midwifery, Queen’s University Belfast, Belfast BT9 7BL, UK
2 shared publications - Helen Noble
School of Nursing and Midwifery, Queen’s University Belfast, Belfast, UK
2 shared publications - Maria Irene Bellini
Department of Surgery, Sapienza University, Rome, Italy
2 shared publications - Michael Corr
Centre for Public Health, Queen’s University Belfast, Belfast, UK
2 shared publications - Amber Orr
Barnsley Hospital NHS Foundation Trust, Barnsley S75 2EP, UK
1 shared publication
Latest Publications
- Open Access
- 1 May 2026
- Published by Frontiers Media SA in Transplant International
- Vol. 39, 16572
Extended criteria deceased donor kidney transplantation in a patient with limited life expectancy
The transformational effects of transplantation are universally recognised. For those with kidney failure the benefits compared to dialysis are notable and extend across all socioeconomic classes, all ethnicities, and all age groups.However the gap between those waiting for a kidney transplant and the relatively static deceased donor pool is increasing. In the UK in 2024-2025 there were almost three times as many people on the waiting list than were transplanted (1).To maximise utilisation of all donated organs, the UK 'Fast Track' scheme is a pathway to expedite organ offering and acceptance processes where there is a high risk of organ discard. It is triggered if the organ is deemed untransplantable, has accrued significant ischaemic time, or there are multiple centre declines because of concern regarding donor or organ quality. There is no detriment in 5-year outcomes of the kidneys that are subsequently transplanted (2).Despite this, the paucity of deceased donor organs means that rationing of transplantation is inevitable. Who should be permitted to benefit from kidney transplantation? The metric most commonly used to evaluate a transplant programme is graft and patient survival, but are there reasonable alternative outcome measures? Might patients' priorities diverge from those of the healthcare professionals? How valid is quality of life rather than quantity of life? We report a case that challenges current perspectives.In 1985 a 15-year-old girl presented with end stage renal disease and commenced haemodialysis.After early graft failure of a first transplant, in 1987 she received a second deceased donor transplant which worked well. It failed after 36 years in 2023 (when the kidney was 95 years old). Haemodialysis recommenced via a left brachiocephalic arterio-venous fistula (AVF).Her clinical course was significant for squamous cell carcinoma (SCC): 2013 local excision of vaginal intraepithelial neoplasia, 2019 radiotherapy for anal SCC followed in 2022 by rectal resection, 2021 right hemi-maxillectomy and radiotherapy for maxillary SCC. Furthermore, she had multiple nonmelanoma skin lesions.The patient was exceptionally keen for a third transplant. She struggled psychologically with dialysisdependency, and its impact not only on her but also her two school-aged children and partner.Physiologically she was much older than her chronological 53 years, and a higher risk candidate from anaesthetic and surgical perspectives. A negative impact on recurrent malignancy of enhanced immunosuppression was considered inevitable.More broadly there was ethical concern about organ utility, given her anticipated life expectancy. This apprehension, along with the modification of the risk-benefit ratio afforded by living donation, meant the team would only consider transplantation if there was an available well-matched living donor. However the patient was very highly sensitized and both volunteers were HLA incompatible. Listing for deceased donor transplantation was deferred.In 2024 repeated intervention was required for her AVF, but in due course no further salvage was possible. Central venous stenoses meant emergency access was achieved via a femoral catheter.Within 24 hours there was an offer of both kidneys from a 76-year-old (donation after circulatory death) donor via the UK Fast Track scheme. There had been an out of hospital cardiac arrest with an hour downtime. Pre-mortal morbidities included hypertension, diabetes mellitus, and vascular disease. The kidneys were declined by all UK transplant centres.Complexity was further increased by the presence of (i) a new left maxillary lesion for which diagnostic imaging and biopsy were awaited (ii) donor specific HLA antibodies at least historically (no up to date testing as patient not on the transplant waiting list).If the current HLA profile was comparable to previously, it was anticipated the crossmatch would be currently negative, historically positive. There was not time for a physical crossmatch prior to transplant given the characteristics of this particular donor. A session of plasma exchange was possible while waiting for current HLA antibody testing results and for kidneys to arrive.The questions considered and discussed openly with the patient included: will this (these) kidney(s) work sufficiently to provide dialysis-independence? Should it be single or dual transplant? Is the risk of rejection too great? Will transplantation shorten life? Will transplantation enhance life? What is the alternative in terms of vascular access?The patient accepted that definitive answers could not be provided. On reflection, she was accepting of the risks and keen to proceed to transplantation.A right renal kidney with ostial atherosclerosis of all three arteries and multiple cysts (the largest 7cm lower pole) was received and transplanted. Histology of a suspicious cyst excised prior to implant, returned as benign. The kidney began to function after three days. No further dialysis was required.There was no rejection. The baseline serum creatinine achieved was ~1.4 mg/dL.The left maxillary lesion was biopsied at time of transplant, and demonstrated malignant squamous cells. Curative resection was not feasible, and treatment with radiotherapy and chemotherapy was initiated. Immunosuppression was tapered quickly and sirolimus substituted for tacrolimus and mycophenolate. There was no rejection. Hospitalisation was required twice for intravenous antibiotic therapy (during chemotherapy treatment). After some months there was escape of control of malignancy with progressive local and disseminated disease. She died at home 13 months after transplantation.If palliative care is defined as 'optimizing quality of life, and mitigating or reducing suffering among people with serious, complex, and often terminal illnesses' this was a palliative transplant. Quality of life was improved, and dialysis-associated suffering reduced, for this patient in her final...
- 1 May 2026
- Published by Frontiers Media SA in Transplant International
- Vol. 39, 16572
Open AccessExtended criteria deceased donor kidney transplantation in a patient with limited life expectancy
The transformational effects of transplantation are universally recognised. For those with kidney failure the benefits compared to dialysis are notable and extend across all socioeconomic classes, all ethnicities, and all age groups.However the gap between those waiting for a kidney transplant and the relatively static deceased donor pool is increasing. In the UK in 2024-2025 there were almost three times as many people on the waiting list than were transplanted (1).To maximise utilisation of all donated organs, the UK 'Fast Track' scheme is a pathway to expedite organ offering and acceptance processes where there is a high risk of organ discard. It is triggered if the organ is deemed untransplantable, has accrued significant ischaemic time, or there are multiple centre declines because of concern regarding donor or organ quality. There is no detriment in 5-year outcomes of the kidneys that are subsequently transplanted (2).Despite this, the paucity of deceased donor organs means that rationing of transplantation is inevitable. Who should be permitted to benefit from kidney transplantation? The metric most commonly used to evaluate a transplant programme is graft and patient survival, but are there reasonable alternative outcome measures? Might patients' priorities diverge from those of the healthcare professionals? How valid is quality of life rather than quantity of life? We report a case that challenges current perspectives.In 1985 a 15-year-old girl presented with end stage renal disease and commenced haemodialysis.After early graft failure of a first transplant, in 1987 she received a second deceased donor transplant which worked well. It failed after 36 years in 2023 (when the kidney was 95 years old). Haemodialysis recommenced via a left brachiocephalic arterio-venous fistula (AVF).Her clinical course was significant for squamous cell carcinoma (SCC): 2013 local excision of vaginal intraepithelial neoplasia, 2019 radiotherapy for anal SCC followed in 2022 by rectal resection, 2021 right hemi-maxillectomy and radiotherapy for maxillary SCC. Furthermore, she had multiple nonmelanoma skin lesions.The patient was exceptionally keen for a third transplant. She struggled psychologically with dialysisdependency, and its impact not only on her but also her two school-aged children and partner.Physiologically she was much older than her chronological 53 years, and a higher risk candidate from anaesthetic and surgical perspectives. A negative impact on recurrent malignancy of enhanced immunosuppression was considered inevitable.More broadly there was ethical concern about organ utility, given her anticipated life expectancy. This apprehension, along with the modification of the risk-benefit ratio afforded by living donation, meant the team would only consider transplantation if there was an available well-matched living donor. However the patient was very highly sensitized and both volunteers were HLA incompatible. Listing for deceased donor transplantation was deferred.In 2024 repeated intervention was required for her AVF, but in due course no further salvage was possible. Central venous stenoses meant emergency access was achieved via a femoral catheter.Within 24 hours there was an offer of both kidneys from a 76-year-old (donation after circulatory death) donor via the UK Fast Track scheme. There had been an out of hospital cardiac arrest with an hour downtime. Pre-mortal morbidities included hypertension, diabetes mellitus, and vascular disease. The kidneys were declined by all UK transplant centres.Complexity was further increased by the presence of (i) a new left maxillary lesion for which diagnostic imaging and biopsy were awaited (ii) donor specific HLA antibodies at least historically (no up to date testing as patient not on the transplant waiting list).If the current HLA profile was comparable to previously, it was anticipated the crossmatch would be currently negative, historically positive. There was not time for a physical crossmatch prior to transplant given the characteristics of this particular donor. A session of plasma exchange was possible while waiting for current HLA antibody testing results and for kidneys to arrive.The questions considered and discussed openly with the patient included: will this (these) kidney(s) work sufficiently to provide dialysis-independence? Should it be single or dual transplant? Is the risk of rejection too great? Will transplantation shorten life? Will transplantation enhance life? What is the alternative in terms of vascular access?The patient accepted that definitive answers could not be provided. On reflection, she was accepting of the risks and keen to proceed to transplantation.A right renal kidney with ostial atherosclerosis of all three arteries and multiple cysts (the largest 7cm lower pole) was received and transplanted. Histology of a suspicious cyst excised prior to implant, returned as benign. The kidney began to function after three days. No further dialysis was required.There was no rejection. The baseline serum creatinine achieved was ~1.4 mg/dL.The left maxillary lesion was biopsied at time of transplant, and demonstrated malignant squamous cells. Curative resection was not feasible, and treatment with radiotherapy and chemotherapy was initiated. Immunosuppression was tapered quickly and sirolimus substituted for tacrolimus and mycophenolate. There was no rejection. Hospitalisation was required twice for intravenous antibiotic therapy (during chemotherapy treatment). After some months there was escape of control of malignancy with progressive local and disseminated disease. She died at home 13 months after transplantation.If palliative care is defined as 'optimizing quality of life, and mitigating or reducing suffering among people with serious, complex, and often terminal illnesses' this was a palliative transplant. Quality of life was improved, and dialysis-associated suffering reduced, for this patient in her final...
- Open Access
- 7 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (4) , 953
The Minimisation of Cardiovascular Disease Screening for Kidney Transplant Candidates
Background: There is increasing evidence that cardiac screening prior to kidney transplantation does not improve its outcomes. However, risk aversion to perioperative events means that, in practice, testing remains common, limiting the availability of ‘real-world’ data to support any change. Our objective was to assess perioperative and 1-year post-transplant cardiovascular events in a kidney transplant candidate cohort who received minimal cardiovascular screening. Methods: The retrospective cohort study included all adult kidney-only transplant recipients in a single UK region between January 2015 and December 2021. Kidney transplant recipients asymptomatic of cardiac disease, even those with established risk factors, did not receive cardiac stress testing. The perioperative and 1-year post-transplant cardiovascular event incidences were examined. Logistic regression was used to identify variables of statistical significance that predicted cardiovascular or cerebrovascular events. Results: A total of 895 recipients fulfilled the inclusion criteria. Prior to transplantation, 209 (23%) recipients had an established cardiac diagnosis, and 193 (22%) individuals had a diagnosis of diabetes. A total of 18 (2%) patients had a perioperative event, and there was a 5.7% incidence of cardiovascular events 1 year post-transplantation. The cardiovascular mortality rate was 0.0% perioperatively, 0.2% at 3 months post-transplant, and 0.2% at 1 year post-transplant. Conclusions: This study demonstrates comparable rates of cardiovascular events despite reduced screening in asymptomatic recipients. It included higher risk individuals who may, on the basis of screening results, have been excluded from transplantation in other programmes. It provides further evidence that extensive cardiac screening prior to kidney transplantation is unlikely to be offset by reduced rates of cardiovascular events.
- 7 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (4) , 953
Open AccessThe Minimisation of Cardiovascular Disease Screening for Kidney Transplant Candidates
Background: There is increasing evidence that cardiac screening prior to kidney transplantation does not improve its outcomes. However, risk aversion to perioperative events means that, in practice, testing remains common, limiting the availability of ‘real-world’ data to support any change. Our objective was to assess perioperative and 1-year post-transplant cardiovascular events in a kidney transplant candidate cohort who received minimal cardiovascular screening. Methods: The retrospective cohort study included all adult kidney-only transplant recipients in a single UK region between January 2015 and December 2021. Kidney transplant recipients asymptomatic of cardiac disease, even those with established risk factors, did not receive cardiac stress testing. The perioperative and 1-year post-transplant cardiovascular event incidences were examined. Logistic regression was used to identify variables of statistical significance that predicted cardiovascular or cerebrovascular events. Results: A total of 895 recipients fulfilled the inclusion criteria. Prior to transplantation, 209 (23%) recipients had an established cardiac diagnosis, and 193 (22%) individuals had a diagnosis of diabetes. A total of 18 (2%) patients had a perioperative event, and there was a 5.7% incidence of cardiovascular events 1 year post-transplantation. The cardiovascular mortality rate was 0.0% perioperatively, 0.2% at 3 months post-transplant, and 0.2% at 1 year post-transplant. Conclusions: This study demonstrates comparable rates of cardiovascular events despite reduced screening in asymptomatic recipients. It included higher risk individuals who may, on the basis of screening results, have been excluded from transplantation in other programmes. It provides further evidence that extensive cardiac screening prior to kidney transplantation is unlikely to be offset by reduced rates of cardiovascular events.
- Open Access
- 15 September 2023
- Published by Frontiers Media SA in Transplant International
- Vol. 36, 11428
When There is No Guidance From the Guidelines: Renal Transplantation in Recipients With Class III Obesity
Whilst renal transplantation is the optimal treatment for many patients with end-stage kidney disease, the latest international guidelines are unable to make recommendations for the management of patients with end-stage kidney stage kidney disease and Class III Obesity (BMI ≥40 kg/m2). Data on all adult patients receiving a kidney-only-transplant in the UK between 2015–2021 were analysed from a prospectively collected database and interrogated across a range of parameters. We then analysed in detail the outcomes of patients transplanted at the highest-volume unit. There were 22,845 renal transplants in the study time-period; just 44 (0.2%) were performed in recipients with a BMI ≥40 kg/m2. Most transplant centres did not transplant any patients in this category. In the centre with the highest volume, there were 21 transplants (9 living donor) performed in 20 individuals (13 male, median age 46 years). One-year patient and death-censored graft survival was 95% and 85%. Successful transplantation is possible in patients with BMI ≥40 kg/m2 but carries additional risk. Obesity should not be the sole factor considered when deciding on transplant suitability. Restricting transplantation to a small number of high-volume centres in each country should be considered to optimize outcomes.
- 15 September 2023
- Published by Frontiers Media SA in Transplant International
- Vol. 36, 11428
Open AccessWhen There is No Guidance From the Guidelines: Renal Transplantation in Recipients With Class III Obesity
Whilst renal transplantation is the optimal treatment for many patients with end-stage kidney disease, the latest international guidelines are unable to make recommendations for the management of patients with end-stage kidney stage kidney disease and Class III Obesity (BMI ≥40 kg/m2). Data on all adult patients receiving a kidney-only-transplant in the UK between 2015–2021 were analysed from a prospectively collected database and interrogated across a range of parameters. We then analysed in detail the outcomes of patients transplanted at the highest-volume unit. There were 22,845 renal transplants in the study time-period; just 44 (0.2%) were performed in recipients with a BMI ≥40 kg/m2. Most transplant centres did not transplant any patients in this category. In the centre with the highest volume, there were 21 transplants (9 living donor) performed in 20 individuals (13 male, median age 46 years). One-year patient and death-censored graft survival was 95% and 85%. Successful transplantation is possible in patients with BMI ≥40 kg/m2 but carries additional risk. Obesity should not be the sole factor considered when deciding on transplant suitability. Restricting transplantation to a small number of high-volume centres in each country should be considered to optimize outcomes.
- Open Access
- 21 April 2023
- Published by Frontiers Media SA in Transplant International
- Vol. 36
Living Donor Kidney Transplantation in Older Individuals: An Ethical Legal and Psychological Aspects of Transplantation (ELPAT) View
Living donor transplantation is the optimal treatment for suitable patients with end-stage kidney disease. There are particular advantages for older individuals in terms of elective surgery, timely transplantation, and early graft function. Yet, despite the superiority of living donor transplantation especially for this cohort, older patients are significantly less likely to access this treatment modality than younger age groups. However, given the changing population demographic in recent decades, there are increasing numbers of older but otherwise healthy individuals with kidney disease who could benefit from living donor transplantation. The complex reasons for this inequity of access are explored, including conscious and unconscious age-related bias by healthcare professionals, concerns relating to older living donors, ethical anxieties related to younger adults donating to aging patients, unwillingness of potential older recipients to consider living donation, and the relevant legislation. There is a legal and moral duty to consider the inequity of access to living donor transplantation, recognising both the potential disparity between chronological and physiological age in older patients, and benefits of this treatment for individuals as well as society.
- 21 April 2023
- Published by Frontiers Media SA in Transplant International
- Vol. 36
Open AccessLiving Donor Kidney Transplantation in Older Individuals: An Ethical Legal and Psychological Aspects of Transplantation (ELPAT) View
Living donor transplantation is the optimal treatment for suitable patients with end-stage kidney disease. There are particular advantages for older individuals in terms of elective surgery, timely transplantation, and early graft function. Yet, despite the superiority of living donor transplantation especially for this cohort, older patients are significantly less likely to access this treatment modality than younger age groups. However, given the changing population demographic in recent decades, there are increasing numbers of older but otherwise healthy individuals with kidney disease who could benefit from living donor transplantation. The complex reasons for this inequity of access are explored, including conscious and unconscious age-related bias by healthcare professionals, concerns relating to older living donors, ethical anxieties related to younger adults donating to aging patients, unwillingness of potential older recipients to consider living donation, and the relevant legislation. There is a legal and moral duty to consider the inequity of access to living donor transplantation, recognising both the potential disparity between chronological and physiological age in older patients, and benefits of this treatment for individuals as well as society.
- Open Access
- 14 February 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (4) , 566
The Educational Needs of Adolescent and Young Adult Renal Transplant Recipients—A Scoping Review
Renal transplantation is the gold-standard treatment for adolescents and young adults with end-stage renal disease. Despite enjoying excellent short-term outcomes, they suffer the worst rates of premature transplant function loss. Health behaviors: such as lack of adherence to immunosuppressive medications, are felt to be the major contributory factor. Understanding the educational needs of young renal transplant recipients allows healthcare practitioners to better support patients in managing their chronic disease. The aim of this scoping review was to understand what is known about their educational needs. A scoping review methodology was followed. Following an online search, study titles, and abstracts were screened for eligibility, followed by full-text assessment and data extraction. Data were qualitatively analyzed using thematic analysis. A total of 29 studies were included in the scoping review. In young people who struggled with self-management, three themes were identified (1) the Needs of the disrupted youth, (2) the Needs of the disorganized youth (3) the Needs of the distressed youth. There was a paucity of research to identify the protective factors that enable young recipients to successfully manage their health. This review outlines current knowledge of the patient education needs of young transplant recipients. It also highlights remaining research gaps that will need to be addressed with future research.
- 14 February 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (4) , 566
Open AccessThe Educational Needs of Adolescent and Young Adult Renal Transplant Recipients—A Scoping Review
Renal transplantation is the gold-standard treatment for adolescents and young adults with end-stage renal disease. Despite enjoying excellent short-term outcomes, they suffer the worst rates of premature transplant function loss. Health behaviors: such as lack of adherence to immunosuppressive medications, are felt to be the major contributory factor. Understanding the educational needs of young renal transplant recipients allows healthcare practitioners to better support patients in managing their chronic disease. The aim of this scoping review was to understand what is known about their educational needs. A scoping review methodology was followed. Following an online search, study titles, and abstracts were screened for eligibility, followed by full-text assessment and data extraction. Data were qualitatively analyzed using thematic analysis. A total of 29 studies were included in the scoping review. In young people who struggled with self-management, three themes were identified (1) the Needs of the disrupted youth, (2) the Needs of the disorganized youth (3) the Needs of the distressed youth. There was a paucity of research to identify the protective factors that enable young recipients to successfully manage their health. This review outlines current knowledge of the patient education needs of young transplant recipients. It also highlights remaining research gaps that will need to be addressed with future research.
- 12 November 2022
- Published by Springer Nature
- p. 105-114
Medical Evaluation of Potential Living Kidney Donors
- 12 November 2022
- Published by Springer Nature
- p. 105-114
Medical Evaluation of Potential Living Kidney Donors
- Open Access
- 23 June 2022
- Published by MDPI AG in Healthcare
- Vol. 10 (7) , 1177
Dialysis, Distress, and Difficult Conversations: Living with a Kidney Transplant
Background: Providing holistic care to kidney patients is important; however, without full consideration of the perspectives of people living with a kidney transplant, the provision of truly ‘holistic healthcare’ cannot be possible. It is imperative to understand patient experiences by including kidney patients in key strategies and future renal service planning. Ignoring these important patient views means that there is a significant risk of inappropriate renal service provision and lack of adequate support, impacting overall health. The aim of this study was to develop an in-depth understanding of the lived experiences of kidney transplant recipients. Methods: A total of 23 participants were recruited between two regional nephrology units within the United Kingdom via clinical gatekeepers. In-depth interviews were undertaken. Interviews were digitally recorded, transcribed verbatim, and subjected to interpretative phenomenological analysis. Results: Two themes emerged: “managing ongoing fears of dialysis, distress, and COVID-19” and “dealing with difficult conversations”. Conclusions: Renal healthcare professionals need to understand more than the biological impact of receiving a kidney transplant. Understanding the holistic and multidomain experiences that these participants experience will help healthcare professionals to recognize the needs of this group and ensure more responsive psychosocial care.
- 23 June 2022
- Published by MDPI AG in Healthcare
- Vol. 10 (7) , 1177
Open AccessDialysis, Distress, and Difficult Conversations: Living with a Kidney Transplant
Background: Providing holistic care to kidney patients is important; however, without full consideration of the perspectives of people living with a kidney transplant, the provision of truly ‘holistic healthcare’ cannot be possible. It is imperative to understand patient experiences by including kidney patients in key strategies and future renal service planning. Ignoring these important patient views means that there is a significant risk of inappropriate renal service provision and lack of adequate support, impacting overall health. The aim of this study was to develop an in-depth understanding of the lived experiences of kidney transplant recipients. Methods: A total of 23 participants were recruited between two regional nephrology units within the United Kingdom via clinical gatekeepers. In-depth interviews were undertaken. Interviews were digitally recorded, transcribed verbatim, and subjected to interpretative phenomenological analysis. Results: Two themes emerged: “managing ongoing fears of dialysis, distress, and COVID-19” and “dealing with difficult conversations”. Conclusions: Renal healthcare professionals need to understand more than the biological impact of receiving a kidney transplant. Understanding the holistic and multidomain experiences that these participants experience will help healthcare professionals to recognize the needs of this group and ensure more responsive psychosocial care.
- 28 May 2022
- Published by Springer Nature
- p. 1513-1522
Running a Living Donor Programme
- Open Access
- 5 July 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (7) , 2118
Living Donor Kidney Transplantation Improves Graft and Recipient Survival in Patients with Multiple Kidney Transplants
Background: Failed kidney transplant recipients benefit from a new graft as the general incident dialysis population, although additional challenges in the management of these patients are often limiting the long-term outcomes. Previously failed grafts, a long history of comorbidities, side effects of long-term immunosuppression and previous surgical interventions are common characteristics in the repeated kidney transplantation population, leading to significant complex immunological and technical aspects and often compromising the short- and long-term results. Although recipients’ factors are acknowledged to represent one of the main determinants for graft and patient survival, there is increasing interest in expanding the donor’s pool safely, particularly for high-risk candidates. The role of living kidney donation in this peculiar context of repeated kidney transplantation has not been assessed thoroughly. The aim of the present study is to analyse the effects of a high-quality graft, such as the one retrieved from living kidney donors, in the repeated kidney transplant population context. Methods: Retrospective analysis of the outcomes of the repeated kidney transplant population at our institution from 1968 to 2019. Data were extracted from a prospectively maintained database and stratified according to the number of transplants: 1st, 2nd or 3rd+. The main outcomes were graft and patient survivals, recorded from time of transplant to graft failure (return to dialysis) and censored at patient death with a functioning graft. Duration of renal replacement therapy was expressed as cumulative time per month. A multivariate analysis considering death-censored graft survival, decade of transplantation, recipient age, donor age, living donor, transplant number, ischaemic time, time on renal replacement therapy prior to transplant and HLA mismatch at HLA-A, -B and -DR was conducted. In the multivariate analysis of recipient survival, diabetic nephropathy as primary renal disease was also included. Results: A total of 2395 kidney transplant recipients were analysed: 2062 (83.8%) with the 1st kidney transplant, 279 (11.3%) with the 2nd graft, 46 (2.2%) with the 3rd+. Mean age of 1st kidney transplant recipients was 43.6 ± 16.3 years, versus 39.9 ± 14.4 for 2nd and 41.4 ± 11.5 for 3rd+ (p < 0.001). Aside from being younger, repeated kidney transplant patients were also more often males (p = 0.006), with a longer time spent on renal replacement therapy (p < 0.0001) and a higher degree of sensitisation, expressed as calculated reaction frequency (p < 0.001). There was also an association between multiple kidney transplants and better HLA match at transplantation (p < 0.0001). A difference in death-censored graft survival by number of transplants was seen, with a median graft survival of 328 months for recipients of the 1st transplant, 209 months for the 2nd and 150 months for the 3rd+ (p = 0.038). The same difference was seen in deceased donor kidneys (p = 0.048), but not in grafts from living donors (p = 0.2). Patient survival was comparable between the three groups (p = 0.59). Conclusions: In the attempt to expand the organ donor pool, particular attention should be reserved to high complex recipients, such as the repeated kidney transplant population. In this peculiar context, the quality of the donor has been shown to represent a main determinant for graft survival—in fact, kidney retrieved from living donors provide comparable outcomes to those from single-graft recipients.
- 5 July 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (7) , 2118
Open AccessLiving Donor Kidney Transplantation Improves Graft and Recipient Survival in Patients with Multiple Kidney Transplants
Background: Failed kidney transplant recipients benefit from a new graft as the general incident dialysis population, although additional challenges in the management of these patients are often limiting the long-term outcomes. Previously failed grafts, a long history of comorbidities, side effects of long-term immunosuppression and previous surgical interventions are common characteristics in the repeated kidney transplantation population, leading to significant complex immunological and technical aspects and often compromising the short- and long-term results. Although recipients’ factors are acknowledged to represent one of the main determinants for graft and patient survival, there is increasing interest in expanding the donor’s pool safely, particularly for high-risk candidates. The role of living kidney donation in this peculiar context of repeated kidney transplantation has not been assessed thoroughly. The aim of the present study is to analyse the effects of a high-quality graft, such as the one retrieved from living kidney donors, in the repeated kidney transplant population context. Methods: Retrospective analysis of the outcomes of the repeated kidney transplant population at our institution from 1968 to 2019. Data were extracted from a prospectively maintained database and stratified according to the number of transplants: 1st, 2nd or 3rd+. The main outcomes were graft and patient survivals, recorded from time of transplant to graft failure (return to dialysis) and censored at patient death with a functioning graft. Duration of renal replacement therapy was expressed as cumulative time per month. A multivariate analysis considering death-censored graft survival, decade of transplantation, recipient age, donor age, living donor, transplant number, ischaemic time, time on renal replacement therapy prior to transplant and HLA mismatch at HLA-A, -B and -DR was conducted. In the multivariate analysis of recipient survival, diabetic nephropathy as primary renal disease was also included. Results: A total of 2395 kidney transplant recipients were analysed: 2062 (83.8%) with the 1st kidney transplant, 279 (11.3%) with the 2nd graft, 46 (2.2%) with the 3rd+. Mean age of 1st kidney transplant recipients was 43.6 ± 16.3 years, versus 39.9 ± 14.4 for 2nd and 41.4 ± 11.5 for 3rd+ (p < 0.001). Aside from being younger, repeated kidney transplant patients were also more often males (p = 0.006), with a longer time spent on renal replacement therapy (p < 0.0001) and a higher degree of sensitisation, expressed as calculated reaction frequency (p < 0.001). There was also an association between multiple kidney transplants and better HLA match at transplantation (p < 0.0001). A difference in death-censored graft survival by number of transplants was seen, with a median graft survival of 328 months for recipients of the 1st transplant, 209 months for the 2nd and 150 months for the 3rd+ (p = 0.038). The same difference was seen in deceased donor kidneys (p = 0.048), but not in grafts from living donors (p = 0.2). Patient survival was comparable between the three groups (p = 0.59). Conclusions: In the attempt to expand the organ donor pool, particular attention should be reserved to high complex recipients, such as the repeated kidney transplant population. In this peculiar context, the quality of the donor has been shown to represent a main determinant for graft survival—in fact, kidney retrieved from living donors provide comparable outcomes to those from single-graft recipients.
- Open Access
- 21 May 2020
- Published by Springer Nature in Cureus
- Vol. 12 (5) , e8217
Hyperamylasemia Post Living Donor Nephrectomy Does Not Relate to Pain
The aetiology of pain after laparoscopic donor nephrectomy remains unclear. Given the proximity of the left kidney to the tail of the pancreas, we aimed to assess whether mobilisation and retrieval of the left kidney might inflame the pancreas, leading to pain and hyperamylasaemia in the post-operative period. In the present study, 16 consecutive live kidney donors were analysed in the same three months period. Amylase levels were measured on days 1 and 2. For each 24-hour period post-operatively analgesia consumption was recorded, as well as pain scores at rest on a visual analogue scale (VAS). Three out of 16 donors presented hyperamylasemia. A multiple regression analysis found levobupivacaine dose, propofol dose, transversus abdominis plane block and day 1 amylase did not significantly predict pain scores. Interestingly, body mass index significantly correlated with increased pain scores (p = 0.041). Also, increasing CO2 insufflation pressure and use of local anaesthetic infusion catheters predicted a decreased deep pain score (p = 0.036 and p = 0.037). There was no correlation of amylase levels and pain scores. Pancreatitis is a rare complication of nephrectomy and no overt cases were seen in the case of donor nephrectomy.
- 21 May 2020
- Published by Springer Nature in Cureus
- Vol. 12 (5) , e8217
Open AccessHyperamylasemia Post Living Donor Nephrectomy Does Not Relate to Pain
The aetiology of pain after laparoscopic donor nephrectomy remains unclear. Given the proximity of the left kidney to the tail of the pancreas, we aimed to assess whether mobilisation and retrieval of the left kidney might inflame the pancreas, leading to pain and hyperamylasaemia in the post-operative period. In the present study, 16 consecutive live kidney donors were analysed in the same three months period. Amylase levels were measured on days 1 and 2. For each 24-hour period post-operatively analgesia consumption was recorded, as well as pain scores at rest on a visual analogue scale (VAS). Three out of 16 donors presented hyperamylasemia. A multiple regression analysis found levobupivacaine dose, propofol dose, transversus abdominis plane block and day 1 amylase did not significantly predict pain scores. Interestingly, body mass index significantly correlated with increased pain scores (p = 0.041). Also, increasing CO2 insufflation pressure and use of local anaesthetic infusion catheters predicted a decreased deep pain score (p = 0.036 and p = 0.037). There was no correlation of amylase levels and pain scores. Pancreatitis is a rare complication of nephrectomy and no overt cases were seen in the case of donor nephrectomy.